Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT
The upgrade reflected the investment firm’s confidence in oral Selective Estrogen Receptor Degrader (SERD), supported by Roche’s encouraging results from the phase 3 trial of giredestrant in the treatment...







